Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp (BCTXW) is a clinical-stage biotechnology leader advancing novel immunotherapies for cancer treatment. This dedicated news hub provides investors and researchers with essential updates on the company’s scientific progress and corporate developments.
Access authoritative information on clinical trial milestones, regulatory filings, and research partnerships related to BriaCell’s innovative platforms including Briavax and Bria-IMT. Our curated news collection helps stakeholders monitor:
- Phase 1/2 and pivotal Phase 3 trial results
- FDA communications and compliance updates
- Intellectual property developments and patent grants
- Collaborative research initiatives with academic institutions
- Peer-reviewed publication highlights
Bookmark this page for streamlined access to verified updates about BriaCell’s cell-based therapies and precision oncology approaches. Always consult primary sources before making investment decisions.
BriaCell Therapeutics, a clinical-stage biotech firm, has closed a $5.0 million registered direct offering with institutional and existing investors, including a director. The offering involves the sale of 2,402,935 common shares and warrants, with each unit priced at $2.00 to $2.215. The proceeds will fund working capital, R&D, a Phase 3 breast cancer study, and legal costs. A.G.P./Alliance Global Partners acted as the sole placement agent. The offering has been conducted under an existing shelf registration statement filed with the SEC.
BriaCell Therapeutics announced a $5.0 million registered direct offering, involving the sale of 2,402,935 common shares or pre-funded warrants and warrants to institutional investors and a director. The shares are priced at $2.00 each for institutional investors and $2.215 for the director, with warrants exercisable at $2.11 within six months and expiring in five years. The proceeds will support working capital, R&D, including a Phase 3 study in advanced breast cancer, and potential share repurchases. The offering closes around May 17, 2024, subject to customary conditions.
FAQ
What is the current stock price of Briacell Therapeutics (BCTXW)?
